The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The last two decades have seen a transformation in the management of metastatic colorectal cancer (mCRC), as first irinotecan and later oxaliplatin, capecitabine and the three approved targeted therapies have been added to 5-fluorouracil (5-FU) as options for treatment of this tumour. These developments have brought with them a significant improvement in outlook for many patients diagnosed with mCRC,...
With an increasing number of options now available for the management of metastatic colorectal cancer (mCRC), clinicians face the challenge of how to use them most effectively. First-line cytotoxic ‘doublets’ increase response rates and time to progression compared with monotherapy. However, five recent studies showed no significant overall survival benefit for first-line combination therapy compared...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.